Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 11—November 2011


Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A, 1998–2007

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at; (4) view/print certificate.

Release date: October 20, 2011; Expiration date: October 20, 2012

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Analyze the prevalence of trimethoprim/sulfamethoxazole resistance among Escherichia coli clonal group A (CGA) isolates

  • Distinguish geographic locations with the highest prevalence of CGA

  • Assess variables that significantly affect the prevalence of CGA

  • Evaluate temporal trends in the prevalence of CGA


Claudia Chesley, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Claudia Chesley has disclosed no relevant financial relationships.


Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.


Disclosures: Megan E. Menard, MS; Tsai-Ling Lauderdale, PhD; Chris Kosmidis, MD; David Gordon, PhD; Joel N. Maslow, MD; and Michael A. Kuskowski, PhD, have disclosed no relevant financial relationships. James R. Johnson, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Merck & Co., Inc., and Rochester Medical Group. Peter Collignon, MD, has disclosed the following relevant financial relationships: served as a speaker at the Zimmer Orthopaedic Meeting in Melbourne, Victoria, Australia. Arjana Andrašević, MD, has disclosed the following relevant financial relationships: served as a speaker or a member of a speakers bureau for Pfizer, Novartis, and MSD. James R. Johnson, MD, on behalf of the Trans-Global Initiative for Antimicrobial Resistance Analysis Investigators, has disclosed no relevant financial relationships.


Article Navigation